Press release
Oncolytic Virus Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Tasly P
Oncolytic Virus Pipeline
Key Takeaways from the Oncolytic Virus Competitive Landscape Report
• DelveInsight's Oncolytic Virus report depicts a robust space with 150+ Oncolytic Virus companies working to develop 175+ pipeline therapies for Oncolytic Virus treatment.
• The leading Oncolytic Virus Companies working in the market include Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN Biosciences, Candel therapeutics, Sorrento Therapeutics, Imugene Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse Therapeutics, and others.
• Promising Oncolytic Virus therapies in the various stages of development include ASP9801, Pembrolizumab, Recombinant oncolytic herpes simplex virus type 1 (R130), Valacyclovir, CF33-hNIS, and others.
• December 2023: Shanghai Yunying Medical Technology announced a study of early phase 1 clinical trials for Recombinant oncolytic herpes simplex virus TypeⅠ(R130). 9 participants are expected to be enrolled for this open Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus, R130 in patients with advanced bone and soft tissue tumors.
• December 2023: TILT Bio Therapeutics Ltd announced a study of Phase 1 clinical trials for TIL-123 and Pembrolizumab. This is an open-label, phase 1, dose-escalation, multicenter, and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with platinum-resistant or refractory ovarian cancer.
• December 2023: Genelux Corporation announced a study of Phase 3 clinical trials for Bevacizumab (or Biosimilar). The OnPrime study is a multicenter, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with platinum-doublet chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer).
Request a sample and discover the recent advances in Oncolytic Virus Drugs @ Oncolytic Virus Competitive Landscape Report- https://www.delveinsight.com/report-store/oncolytic-virus-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Oncolytic Virus report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the Oncolytic Virus report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.
Oncolytic Virus Overview
Oncolytic viruses (OVs) are organisms able to identify, infect, and lyse different cells in the tumor environment, aiming to stabilize and decrease the tumor progression. They are able to infect abnormal cells through specific targets, such as nuclear transcription factors and among them human telomerase reverse transcriptase, prostate specific antigen, cyclooxygenase-2, osteocalcin, and surface markers as prostate-specific membrane antigen, folate receptor, CD20, endothelial growth factor receptor, and Her2/neu, which are substances produced by the tumor cells.
Find out more about Oncolytic Virus Analytical Perspective: In-depth Commercial Assessment @ Oncolytic Virus Collaboration Analysis by Companies- https://www.delveinsight.com/sample-request/oncolytic-virus-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Oncolytic Virus Companies and Therapies
• SillaJen Inc.: Pexa-Vec
• Candel Therapeutics: CAN-2409
• CG Oncology: CG0070
• Virogin Biotech: VG161
• Daiichi Sankyo: Teserpaturev
Oncolytic Virus Clinical Assessment of Products
The Oncolytic Virus Competitive Landscape report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type.
Oncolytic Virus Report Assessment
• Oncolytic Virus Company Analysis
• Oncolytic Virus Therapeutic Assessment
• Oncolytic Virus Pipeline Assessment
• Inactive Oncolytic Virus Drugs Assessment
• Oncolytic Virus Unmet Needs
Learn more about the emerging Oncolytic Virus Competitive Landscape @ Oncolytic Virus Market Drivers and Barriers, Unmet Needs- https://www.delveinsight.com/sample-request/oncolytic-virus-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Oncolytic Virus Competitive Landscape Report
• Coverage- Global
• Oncolytic Virus Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN Biosciences, Candel therapeutics, Sorrento Therapeutics, Imugene Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse Therapeutics, and others.
• Oncolytic Virus therapies- ASP9801, Pembrolizumab, Recombinant oncolytic herpes simplex virus type 1 (R130), Valacyclovir, CF33-hNIS, and others.
• Oncolytic Virus Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type
Dive deep into rich insights for new drugs for Oncolytic Virus Product Developmental Activities, Visit @ Oncolytic Virus Research and Development Activities- https://www.delveinsight.com/sample-request/oncolytic-virus-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Oncolytic Virus: Overview
4. Oncolytic Virus Pipeline Therapeutics
5. Oncolytic Virus Therapeutic Assessment
6. Oncolytic Virus - DelveInsight's Analytical Perspective
7. SillaJen, Inc.
8. Pexa-Vec: SillaJen, Inc.
9. Drug profiles in the detailed report…..
10. Candel Therapeutics
11. CAN-2409: Candel Therapeutics
12. Drug profiles in the detailed report…..
13. CG Oncology
14. CG0070: CG Oncology
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Oncolytic Virus Key Companies
18. Oncolytic Virus Key Products
19. Oncolytic Virus Unmet Needs
20. Oncolytic Virus Market Drivers and Barriers
21. Oncolytic Virus Future Perspectives and Conclusion
22. Oncolytic Virus Analyst Views
23. Oncolytic Virus Key Companies
24. Appendix
For further information on the Oncolytic Virus Report @ Oncolytic Virus Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/oncolytic-virus-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Info:
Ankit Nigam
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oncolytic Virus Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Tasly P here
News-ID: 3472474 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Oncolytic
Prominent Oncolytic Virus Therapy Market Trend for 2025: Accelerating Oncolytic …
Which drivers are expected to have the greatest impact on the over the oncolytic virus therapy market's growth?
The rise in cancer incidences is likely to fuel the expansion of the oncolytic virus therapy market. Oncolytic virus therapy is gaining traction as an appealing approach to treating cancer- a collection of diseases marked by abnormal cell growth and proliferation. This therapeutic strategy effectively targets and eliminates cancer cells, while also triggering…
Enhancing the Immune Response with Oncolytic Virus Therapy
Oncolytic virus therapy is revolutionizing cancer treatment by harnessing the unique characteristics of viruses to specifically target and destroy cancer cells. This cutting-edge approach represents a significant advancement in cancer care, offering renewed hope for patients with different types of cancer.
Download Report:
https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-oncolytic-virus-therapy-market-oncolytic-virus-fda-approved-oncolytic-virus-clinical-trilas
The essence of oncolytic virus therapy is based on genetically modified viruses that can selectively attack and kill cancer cells while leaving healthy tissue unharmed. These engineered viruses take…
Creative Biolabs Unleashes Solutions to Validate Oncolytic Virotherapy
Creative Biolabs introduces safety and efficacy validation strategies for oncolytic virotherapy.
New York, USA - June 17, 2024 - Oncolytic virotherapy appears as a new paradigm in cancer immunotherapy that enrolls specifically engineered viruses to selectively infect and kill cancer cells, some of which have marched into clinical trials, like adenoviruses, HSV, reovirus, vaccinia virus, and measles. With so many other candidates still on their preclinical journey, the requests to validate…
Oncolytic Virus Competitive Landscape 2023 (Updated)
DelveInsight's, "Oncolytic Virus Competitive Landscape 2023" report provides comprehensive insights about 150+ Oncolytic Virus Companies and 175+ drugs in the Oncolytic Virus Competitive landscape. It covers the Oncolytic Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Oncolytic Virus Competitive Landscape Report
• DelveInsight's Oncolytic Virus report depicts a robust space with 150+ Oncolytic…
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
Mechanism…
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
